stockrowIncyte Corporation
INCYIncyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −277.9%
- Free cash flow
- −233.0%
- Total debt
- −10.5%
Quarter to September 2026, against a year earlier
Follow INCY
Alert me
Incyte Corporation (INCY) Return on assets
Incyte Corporation's return on assets over the twelve months to 30 September 2026 was 5.92%, down 14.8 percentage points from fiscal 2025 (20.8%). Over the past ten years it has ranged from −15.9% (fiscal 2017) to 22.3% (fiscal 2021); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −28.4%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 20.8% | 20.22 |
| FY2024 | 0.53% | (8.94) |
| FY2023 | 9.47% | 3.15 |
| FY2022 | 6.32% | (16.01) |
| FY2021 | 22.3% | 30.79 |
| FY2020 | −8.46% | (23.18) |
| FY2019 | 14.7% | 10.29 |
| FY2018 | 4.43% | 20.32 |
| FY2017 | −15.9% | (23.77) |
| FY2016 | 7.88% | 7.16 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 41.3% |
| EXEL Exelixis, Inc. compare | 33.2% |
| GMAB Genmab A/S Sponsored ADR compare | 7.31% |
| INCY Incyte Corporation | 5.92% |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.76% |
| ROIV Roivant Sciences Ltd. compare | −6.86% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −28.4% |
| Market median | 0.08% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement